PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Voluntary Share Lock-Up, Engagement of Gold Standard Media for Marketing and Consulting Services

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced that certain shareholders have agreed to a voluntary resale restriction period covering 17,840,000 common shares extending the period of time before the shares become free trading to July 15, 2020. According to the update, these shares were previously only subject to a statutory hold period. In addition, Champignon Brands also announced its engagement of Gold Standard Media, LLC (“GSM”) to provide marketing and consulting services to raise public awareness of the company, with a specific emphasis on its North American clinical expansion. GSM is a Georgetown, TX-based limited liability company existing under the laws of the state of Texas.

To view the full press release, visit http://ibn.fm/5JXM2

About Champignon Brands Inc.

Champignon Brands is focused on the formulation and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.ChampignonBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM

About PsychedelicNewsWire

 PsychedelicNewsWire (PNW) is a far-out information destination focused on (1) delivering the freshest headlines on psychedelics and ‘shrooms, (2) issuing PsychedelicNewsBreaks that are specially crafted to keep the grooviest investors in-the-know, (3) laying down the choicest enhancements for corporate news releases, (4) doing our public and private client-partners a solid with full-service distribution and social media services and (5) taking custom-built corporate communication solutions to the max. PNW has a totally awesome spot in the booming psychedelics space, and our ace team of journalists is always grinding to help our growing roster of clients reach a sizable audience of investors, consumers and media outlets. We’ve got a network of more than 5,000 key syndication outlets to help you deliver dy-no-mite visibility, recognition and content within the psychedelic industry. PsychedelicNewsWire (PNW) is where PSYCHEDELIC news, content and information converge.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

PsychedelicNewsBreaks – Psychedelic Therapeutics and Drug Development Conference Partners with PsychedelicNewsWire as Official Media Sponsor

The Psychedelic Therapeutics and Drug Development announced that PsychedelicNewsWire (“PNW), a specialized communications platform for…

11 months ago

PsychedelicNewsBreaks – 4th Annual Psychedelic Therapeutics and Drug Development Conference to Bridge Gaps in Research and Development of Therapeutic Psychedelics

Arrowhead Sci-Tech Conferences and Events today announced the 4th Annual Psychedelic Therapeutics and Drug Development…

11 months ago

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a…

12 months ago

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at the 27th Annual Milken Institute Global Conference

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative…

12 months ago

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Announces Celly Nu, Six+One Collaboration to Launch unbuzzd(TM)

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) today provided an update by way of a…

12 months ago

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Issues Update on Celly Nu’s Pending Launch of unbuzzd(TM)

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) today provided an update by way of a…

12 months ago